Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EBIT (2019 - 2025)

Volitionrx's EBIT history spans 9 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, EBIT rose 16.66% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached -$21.7 million, up 19.56%, while the annual FY2025 figure was -$21.7 million, 19.56% up from the prior year.
  • EBIT reached -$4.8 million in Q4 2025 per VNRX's latest filing, up from -$5.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$4.8 million in Q4 2025 to a low of -$9.5 million in Q2 2023.
  • Average EBIT over 5 years is -$7.2 million, with a median of -$7.6 million recorded in 2021.
  • Peak YoY movement for EBIT: tumbled 67.89% in 2021, then skyrocketed 34.14% in 2025.
  • A 5-year view of EBIT shows it stood at -$8.8 million in 2021, then rose by 8.81% to -$8.0 million in 2022, then decreased by 9.11% to -$8.7 million in 2023, then soared by 33.86% to -$5.8 million in 2024, then grew by 16.66% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNRX's EBIT are -$4.8 million (Q4 2025), -$5.1 million (Q3 2025), and -$6.3 million (Q2 2025).